Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Devimistat (formerly also known as CPI613; CPI 613; CPI-613), a synthetic lipoate analog, is a novel and potent inhibitor of pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase with potential chemopreventive and antineoplastic activities. It disrupts mitochondrial metabolism and shows strong antitumor activity. Devimistat inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase in NCI-H460 cell line, it disrupts tumor cell mitochondrial metabolism. CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells.
ln Vitro |
GPM-2 stomach cancer cells undergo apoptosis when exposed to devimistat. Devimistat specifically targets a modified version of mitochondrial energy metabolism that tumor cells use. Devimistat causes alterations in the cellular redox state and mitochondrial enzyme activity, which result in cell death, including apoptosis [1].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Sakuratani T, et al. Downregulation of ARID1A in gastric cancer cells: a putative protective molecular mechanism against the Harakiri-mediated apoptosis pathway. Virchows Arch. 2021;478(3):401-411.
|
Molecular Formula |
C22H28O2S2
|
---|---|
Molecular Weight |
388.59
|
CAS # |
95809-78-2
|
Related CAS # |
Devimistat-d10;2586055-61-8
|
SMILES |
O=C(O)CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2
|
Chemical Name |
6,8-bis(benzylthio)octanoic acid
|
Synonyms |
CPI613; CPI-613; Devimistat; CPI 613
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2 mg/mL (5.15 mM) in 2% DMSO + 40% PEG300 + 5% Tween80 + 53% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2 mg/mL (5.15 mM) (saturation unknown) in 2% DMSO 98% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: 1% DMSO+30% polyethylene glycol+1% Tween 80:30 mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5734 mL | 12.8670 mL | 25.7341 mL | |
5 mM | 0.5147 mL | 2.5734 mL | 5.1468 mL | |
10 mM | 0.2573 mL | 1.2867 mL | 2.5734 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05926206 | Withdrawn | Drug: Devimistat Drug: Modified FOLFIRINOX |
Metastatic Pancreatic Adenocarcinoma | University of Michigan Rogel Cancer Center |
July 2023 | Phase 1 Phase 2 |
NCT05070104 | Withdrawn | Drug: CPI-613 Drug: modified FFX |
C04.588.274.476.411.307 | Cornerstone Pharmaceuticals | March 30, 2023 | Phase 1 |
NCT05733000 | Recruiting | Procedure: Computed Tomography Drug: Devimistat |
Advanced Biliary Tract Carcinoma Advanced Colorectal Carcinoma |
Northwestern University | March 8, 2023 | Phase 2 |
NCT05325281 | Recruiting | Drug: CPI-613® (Dose level - 1.0 250 mg/m^2) |
Pancreas Adenocarcinoma | Medical College of Wisconsin | October 31, 2022 | Phase 1 |